Yan Cheng
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Instructor
Also affiliated: University of Notre Dame (2004); Tongji University (2000); National Institutes of Health (2011); Central South University (2023); University of British Columbia (2014–2015); China Pharmaceutical University (2015–2020); Okayama University (2013); University of New Mexico (2013); Anhui Medical University (2024); Peking University (2020–2022); Medical College of Wisconsin (2019–2022); University of Utah (2013–2019); Research Institute of Disinfectology Rospotrebnadzor (2019); Yidu Central Hospital of Weifang (2018–2019); Optum (United States) (2015); The First People’s Hospital of Lianyungang (2021); Winthrop Rockefeller Foundation (2021–2025); Peking University First Hospital (2020–2022); Shanghai Institute of Optics and Fine Mechanics (2008); National Cancer Institute (2011–2014); Xian Yang Central Hospital (2021); Second Affiliated Hospital of Anhui Medical University (2024); First Affiliated Hospital of Zhengzhou University (2021); Third Xiangya Hospital (2023); First Hospital of Xi'an (2018); State Key Laboratory of Natural Medicine (2015–2018); University of Montana (2016); Henan Normal University (2008); University of Pennsylvania (2000); Tsinghua University (2013–2025)
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Yan Cheng's research focuses on understanding the biology of tumor risk genes, the role of neural components and immune cells within the tumor microenvironment, and the development of immune-based cancer therapies. Cheng received a Ph.D. in tumor biology and immunology from China Pharmaceutical University and completed postdoctoral training at the Medical College of Wisconsin, where research centered on multiple myeloma.
Currently an Instructor at the University of Arkansas for Medical Sciences, Cheng's work has led to publications investigating therapeutic approaches for multiple myeloma, including bispecific CAR-T cells targeting BCMA and CD24. Other research areas include the impact of gene expression, such as FOXM1 and NEK2, on cancer cell metabolism, immune suppression, and disease progression. Cheng has also explored the role of exosomal long non-coding RNAs in cancer cell resistance and the mechanisms by which specific proteins, like CST6, affect bone disease associated with multiple myeloma. Collaborative efforts at the University of Arkansas for Medical Sciences involve researchers such as Fumou Sun, Fenghuang Zhan, John D. Shaughnessy, and Guido Tricot, with whom Cheng has co-authored numerous publications.
Cheng's scholarly output includes 105 publications and an h-index of 26, with over 2,200 citations. The researcher's work aligns with ongoing efforts to elucidate complex disease mechanisms and identify novel treatment strategies in oncology.
Metrics
- h-index: 26
- Publications: 105
- Citations: 2,255
Selected Publications
-
Single Cell Analysis of the Tumor Microenvironment Landscape Across the Disease Spectrum of Multiple Myeloma (2026)
-
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025)
-
Abstract 860: BCMA CAR-T cells releasing mutant CST6 N137D proteins further improve therapeutic effects in multiple myeloma (2025)
-
Cystatin M/E Ameliorates Multiple Myeloma-Induced Hyper Osteolytic Bone Resorption (2025)
-
Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages (2024)
-
The Role of CST6 in Immunosuppression in the Multiple Myeloma Microenvironment (2024)
-
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages (2024)
-
Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing (2024)
-
Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems (2024)
-
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth (2024)
-
BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions (2023)
-
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma (2023)
-
P-066 BCMA-CAR-T cells with synthetic circuits of CST6 lyse tumor cells and suppress osteolytic lesions in multiple myeloma (2023)
-
IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma (2023)
-
CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation (2022)
Collaboration Network
Top Collaborators
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
Showing 5 of 15 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
- BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions
Showing 5 of 12 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
Showing 5 of 11 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
Showing 5 of 11 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
- BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions
Showing 5 of 9 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
Showing 5 of 8 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
Showing 5 of 8 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
Showing 5 of 8 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
- BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions
Showing 5 of 8 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- Critical Role for Cap-Independent c-MYC Translation in Progression of Multiple Myeloma
- Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing
Showing 5 of 7 shared publications
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions
- Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma
- P-066 BCMA-CAR-T cells with synthetic circuits of CST6 lyse tumor cells and suppress osteolytic lesions in multiple myeloma
Showing 5 of 7 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions
- NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
Showing 5 of 7 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
- Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing
- NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
Showing 5 of 7 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
Showing 5 of 7 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
- BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions
Showing 5 of 7 shared publications
Similar Researchers
Based on overlapping research topics